Filing Flows › CG Oncology (CGON) › Q1 2026
CG Oncology (CGON) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 8, 2026
CG Oncology (CGON) reported revenue of $1.1M for the first quarter 2026 (Q1 2026), up 21-fold from a year earlier and -53% from the quarter before.
CG Oncology, Q1 2026: revenue $1.1M (21× year over year), net loss $60.2M, operating cash flow −$56.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | -53% | 21× |
| Operating profit | −$66.4M | — | — |
| Net earnings | −$60.2M | — | — |
| Operating cash flow | −$56.9M | — | — |
What changed
Revenue was $1.1M in Q1 2026, up 1983% year over year and down 53% from the previous quarter. Commercial and Development Revenue was the largest line at 99% of revenue. License and Collaboration Revenue declined 73%.
Operating costs exceeded revenue by $66.4M, an operating margin of -6130.1%. Total costs grew 60% against revenue growth of 1983%. The fastest-growing cost line was Research & development (+59%). The quarter ended with a net loss of $60.2M, wider than the previous quarter's $41.3M loss.
Operating cash flow was −$56.9M. Non-cash charges added back $841K of depreciation and amortization and $6.5M of share-based compensation. Working capital and other items used $4.1M. Capital expenditures of $304K exceeded it, leaving free cash flow of −$57.2M.
Questions
What was CG Oncology's revenue in the first quarter 2026?
CG Oncology (CGON) reported revenue of $1.1M for the first quarter 2026 (Q1 2026), up 21-fold from a year earlier and -53% from the quarter before.
Source: CG Oncology 10-Q on SEC EDGAR.